Nystatin Oral Suspension USP [100,000 units per mL]

Manufacturer
Pharmaceutical Associates, Inc.
Effective date
2022-01-13
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
9
Source
full-release
Hydrated at
2026-05-31 20:38:54

Label at a glance#

ProductNystatin
Active ingredientNYSTATIN
Label structure13 sections

Indications and uses

Nystatin oral suspension is indicated for the treatment of candidiasis in the oral cavity.

Dosage and administration

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes). NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective. CHILDREN AND ADULTS: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth)...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only

DESCRIPTION

DESCRIPTION SECTION

Nystatin is an antimycotic polyene antibiotic obtained from Streptomyces noursei. Structural formula:

nystatin chemical structurenystatin chemical structure

C 47H 75NO 17     MW 926.13

Nystatin Oral Suspension USP, for oral administration, contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol (≤ 1% v/v), artificial peppermint flavor, cherry flavor, citric acid, D&C Yellow No. 10, FD&C Red No. 40, glycerin, magnesium aluminum silicate, methylparaben, potassium phosphate dibasic, propylene glycol, propylparaben, purified water and sucrose.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Pharmacokinetics

PHARMACOKINETICS SECTION

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology

MICROBIOLOGY SECTION

Nystatin is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. Candida albicans demonstrates no significant resistance to nystatin in vitro on repeated subculture in increasing levels of nystatin; other Candida species become quite resistant. Generally, resistance does not develop in vivo. Nystatin acts by binding to sterols in the cell membrane of susceptible Candida species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Nystatin oral suspension is indicated for the treatment of candidiasis in the oral cavity.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects Category C

TERATOGENIC EFFECTS SECTION

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General).

Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

Dermatologic: Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

Other: Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

OVERDOSAGE

OVERDOSAGE SECTION

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (See CLINICAL PHARMACOLOGY, Pharmacokinetics).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans.

HOW SUPPLIED

HOW SUPPLIED SECTION

Nystatin Oral Suspension USP, 100,000 USP Nystatin Units per mL, is available in a cherry, peppermint flavored, light creamy yellow, ready-to-use suspension, supplied in the following oral dosage forms:

NDC 0121-0810-02:  2 fl oz (60mL) bottle with calibrated dropper

NDC 0121-0810-16:  16 fl oz (473mL) bottle

NDC 0121-4810-05:  5mL unit dose cup

NDC 0121-4810-40:  Case contains 40 unit dose cups of 5mL (0121-4810-05) packaged in 
                                  4 trays of 10 unit dose cups each.

Storage

STORAGE AND HANDLING SECTION

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Avoid freezing.

SPL UNCLASSIFIED SECTION

R10/16

Pharmaceutical Associates, Inc.
Greenville, SC 29605
www.paipharma.com

PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

60 mL

NDC 0121-0810-02

Nystatin Oral Suspension, USP

100,000 units per mL

SHAKE WELL BEFORE USING

Packaged with Calibrated Dropper

DO NOT USE IF TAMPER EVIDENT
SEAL IS BROKEN OR MISSING. 

Rx ONLY

Pharmaceutical Associates, Inc.

Greenville, SC 29605

Each mL of cherry, peppermint flavored
oral suspension contains 100,000 units
Nystatin, USP and alcohol (≤ 1% v/v).

USUAL DOSAGE: For Infants: 2 mL(200,000 units) four times daily (in infants andyoung children, use dropper to place one half of dose in each side of the mouth and avoid feeding feeding for 5 to 10 minutes). See insert. 

WARNINGS:  Keep this and all drugs out of reach of children. In case of accidental overdose, seek professional assistance orcontact a Poison Control Center immediately.

Keep tightly closed. Protect from light.

Store at 20° to 25°C (68° to 77°F)

[See USP Controlled Room Temperature}. AVOID FREEZING

R04/17

X01810020417

60 mL bottle label60 mL bottle label

PRINCIPAL DISPLAY PANEL - 5 mL Unit Dose Cup Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Delivers 5 mL

NDC 0121-4810-05

N YSTATIN
O RAL
S USPENSION , USP

500,000 units / 5 mL

Alcohol ≤ 1% v/v   SHAKE WELL

Rx ONLY

FOR INSTITUTIONAL USE ONLY

PHARMACEUTICAL ASSOCIATES, INC.,
GREENVILLE, SC 29605

SEE INSERT

A48100500

5 mL unit dose cup label5 mL unit dose cup label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
312055nystatin 100,000 UNT/mL Oral SuspensionPSN9
312055nystatin 100000 UNT/ML Oral SuspensionSCD9
312055nystatin 100,000 UNT/ML Oral SuspensionSY9
312055nystatin 500,000 UNT per 5 ML Oral SuspensionSY9

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
NYSTATIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
e29fe634-dc25-094c-c77f-5d09c3eceb3eProduct name520260107
4b7700e3-6e0e-45e5-9d22-6f754d61386eProduct name220250304
e57b6340-9387-3f9a-7307-511c81791375Product name320221214
544f8e8d-6389-eeeb-9586-aa447c08dcc7Product name520210614
1629e00f-54fb-4a43-8306-b58442b23902Product name920200430
854ec07b-1cd7-a5db-235a-7aa24d3cf97aProduct name320180628
19b9f4c1-15e9-edcc-4c16-f01ecfb5c549Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0121-0810-02Nystatin60 mL in 1 BOTTLE, DROPPERSUSPENSION609
0121-0810-16Nystatin473 mL in 1 BOTTLESUSPENSION4739
0121-4810-00Nystatin10 in 1 TRAYSUSPENSION109
0121-4810-00Nystatin10 in 1 CASESUSPENSION109
0121-4810-05Nystatin5 mL in 1 CUP, UNIT-DOSESUSPENSION59
0121-4810-40Nystatin10 in 1 TRAYSUSPENSION109
0121-4810-40Nystatin4 in 1 CASESUSPENSION49
0121-4810-50Nystatin5 in 1 CASESUSPENSION59
0121-4810-50Nystatin10 in 1 PACKAGESUSPENSION109

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0121-0810NYSTATIN SUSPENSION [PHARMACEUTICAL ASSOCIATES, INC.]9Current NDC, Legacy NDC, 2 package rows20220114_31e3da10-5a7b-4bc5-8a4f-3e786b64c13a.zip
0121-4810NYSTATIN SUSPENSION [PHARMACEUTICAL ASSOCIATES, INC.]9Current NDC, Legacy NDC, 7 package rows20220114_31e3da10-5a7b-4bc5-8a4f-3e786b64c13a.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0121-0810-02ML - Milliliter0121-081074585cc8-9e6f-4d89-9243-28d79ee1f4ee12016-09-02
0121-0810-16ML - Milliliter0121-0810589842bf-fdae-4623-802f-571932da0a8012016-09-02

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 13 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0121-08100121-0810-02, 0121-0810-16
0121-48100121-4810-05, 0121-4810-40, 0121-4810-00, 0121-4810-50

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 26 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A203621-001NYSTATINNYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A203621-001AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-0784e616aacf4f…
2026-08-18 06:07:402026-07A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-0731067a03dcf5…
2025-08-23 18:47 UTC2025-08A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-076a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-0703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-072680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-075bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-0779d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-071e350fbaab3a…
2024-05-31 18:47 UTC2024-05A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-078072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-075c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-075d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-074b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-0774a2ff9319b5…
2022-03-09 01:35 UTC2022-03A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-0787673890dc5c…
2021-03-12 10:30 UTC2021-03A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-075aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-078869cabd3fbd…
2020-11-12 02:37 UTC2020-11A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07c0c555d07b60…
2019-12-14 00:12 UTC2019-12A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-073f01610625f2…
2019-09-15 20:21 UTC2019-09A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07b00525d2431f…
2019-07-19 19:46 UTC2019-07A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-076a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-071c564ffb4f44…
2023-12-20 04:57 UTC2023-12A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-079b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-073f0d92c62455…
2023-05-13 08:27 UTC2023-05A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07053a50430f4f…
2023-01-26 05:58 UTC2023-01A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-073bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-073a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A203621-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA2016-01-07f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A203621-001AA184e616aacf4f…
2026-08-18 06:07:402026-07A203621-001AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A203621-001AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A203621-001AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08A203621-001AA16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A203621-001AA1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A203621-001AA1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A203621-001AA103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A203621-001AA12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A203621-001AA15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A203621-001AA1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A203621-001AA1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A203621-001AA179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A203621-001AA1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A203621-001AA11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A203621-001AA18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A203621-001AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A203621-001AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A203621-001AA14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A203621-001AA174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A203621-001AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A203621-001AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A203621-001AA187673890dc5c…
2021-03-12 10:30 UTC2021-03A203621-001AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A203621-001AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A203621-001AA1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A203621-001AA13f01610625f2…
2019-09-15 20:21 UTC2019-09A203621-001AA1b00525d2431f…
2019-07-19 19:46 UTC2019-07A203621-001AA1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A203621-001AA16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A203621-001AA11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A203621-001AA1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A203621-001AA1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A203621-001AA19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A203621-001AA1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A203621-001AA13f0d92c62455…
2023-05-13 08:27 UTC2023-05A203621-001AA1053a50430f4f…
2023-01-26 05:58 UTC2023-01A203621-001AA13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A203621-001AA13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A203621-001AA1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
NystatinNYSTATINPharmaceutical Associates, Inc.31e3da10-5a7b-4bc5-8a4f-3e786b64c13a2022-01-13Adverse reactionsExact identifier
ndc (package): 0121-4810-05
ndc (package): 0121-4810-50
ndc (package): 0121-0810-16
ndc (package): 0121-0810-02
ndc (package): 0121-4810-00
ndc (package): 0121-4810-40
ndc (product): 0121-0810
ndc (product): 0121-4810
ndc11 (package): 00121481005
ndc11 (package): 00121081002
ndc11 (package): 00121481000
ndc11 (package): 00121081016
ndc11 (package): 00121481040
ndc11 (package): 00121481050
spl id: d57cde69-0eb9-180d-e053-2995a90a33aa
spl set id: 31e3da10-5a7b-4bc5-8a4f-3e786b64c13a

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.